Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Double balloon enteroscopy: a 2 year experience.
Lahat A, Nadler M, Simon C, Lahav M, Novis B, Bar-Meir S. Lahat A, et al. Among authors: lahav m. Isr Med Assoc J. 2009 Aug;11(8):456-9. Isr Med Assoc J. 2009. PMID: 19891231 Free article.
Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma.
Yablecovitch D, Ben-Horin S, Picard O, Yavzori M, Fudim E, Nadler M, Levy I, Sakhnini E, Lang A, Engel T, Lahav M, Saker T, Neuman S, Selinger L, Dvir R, Raitses-Gurevich M, Golan T, Laish I. Yablecovitch D, et al. Among authors: lahav m. Clin Transl Gastroenterol. 2022 May 1;13(5):e00473. doi: 10.14309/ctg.0000000000000473. Clin Transl Gastroenterol. 2022. PMID: 35297817 Free PMC article.
Serum matrix metalloproteinase-7, Syndecan-1, and CA 19-9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma.
Yablecovitch D, Nadler M, Ben-Horin S, Picard O, Yavzori M, Fudim E, Duchan MT, Sakhnini E, Lang A, Lahav M, Saker T, Neuman S, Selinger L, Freitz B, Dvir R, Raitses-Gurevich M, Golan T, Levy I, Laish I. Yablecovitch D, et al. Among authors: lahav m. Cancer Med. 2024 Sep;13(17):e70144. doi: 10.1002/cam4.70144. Cancer Med. 2024. PMID: 39263943 Free PMC article.
Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E. Zorde Khvalevsky E, et al. Among authors: lahav m. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2. Proc Natl Acad Sci U S A. 2013. PMID: 24297898 Free PMC article.
419 results